DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107. - Morrow MP; Gillespie E; Sylvester A; Amin MR; Belafsky PC; Best SR; Friedman AD; Klein AM; Lott DG; Mau T; Paniello RC; Pransky SM; et al. (Nature communications, 2025)